Irbesartan was renoprotective in patients with type 2 diabetes, hypertension, and microalbuminuria.

Patients 611 patients between 30 and 70 years of age who had type 2 diabetes; hypertension defined as systolic blood pressure > 135 mm Hg or diastolic blood pressure > 85 mg, or both; persistent microalbuminuria defined as an albumin excretion rate of 20 to 200 ìg/minute; and a serum creatinine concentration < 133 ìmol/l for men or < 97 ìmol/l for women. Exclusion criteria were non-diabetic kidney disease, cancer, fatal disease, or indication for angiotensin converting enzyme (ACE) inhibitors or ARAs. 590 of 611 (97%) patients (mean age 58 y, 68% men) completed follow up.